Inhibition of mesothelin as a novel strategy for targeting cancer cells

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Wang, Kun ^a   Bodempudi, Vidya ^b   Liu, Zhengian ^a   Borrego Diaz, Emma ^a   Yamoutpoor, Farnaz ^a   Meyer, Anna ^b   Woo, Richard A ^c   Pan, Weihong ^a   Dudek, Arkadiusz Z ^b   Olyaee, Mojtaba S ^a   Esfandyari, Tuba ^a   Farassati, Faris ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c SOUTHERN ILLINOIS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; MESOTHELIN; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE 3; ONCOPROTEIN; PROTEIN ERO1; PROTEIN KINASE B; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN;

ARTICLE; CANCER CELL; CANCER INHIBITION; CELL INVASION; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVITY; EPITHELIAL MESENCHYMAL TRANSITION; GENE SEQUENCE; GENE SILENCING; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; LENTIVIRINAE; MESOTHELIOMA; NUCLEOTIDE SEQUENCE; OVARY CANCER; PANCREAS CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; ANIMAL; CELL CYCLE; CELL MOTION; CELL PROLIFERATION; CELL SURVIVAL; GENETICS; METABOLISM; MOUSE; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

LENTIVIRUS;

ANIMALS; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; GENE KNOCKDOWN TECHNIQUES; GPI-LINKED PROTEINS; HUMANS; MICE; MICRORNAS; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 84859228476     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0033214     Document Type: Article

References (57)

1. Chang K, Pastan I, (1996) Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A 93: 136-140.
2. Glass JP, Parasher G, Arias-Pulido H, Donohue R, Cerilli LA, (2011) Mesothelin and GPR30 Staining Among a Spectrum of Pancreatic Epithelial Neoplasms. Int J Surg Pathol.
3. Iacobuzio-Donahue CA, Ashfaq R, Maitra A, Adsay NV, Shen-Ong GL, et al. (2003) Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res 63: 8614-8622.
4. Rump A, Morikawa Y, Tanaka M, Minami S, Umesaki N, et al. (2004) Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem 279: 9190-9198.
5. Hellstrom I, Hellstrom KE, (2011) fTwo novel biomarkers, mesothelin and HE4, for diagnosis of ovarian carcinoma. Expert Opin Med Diagn 5: 227-240.
6. Ho M, Bera TK, Willingham MC, Onda M, Hassan R, et al. (2007) Mesothelin expression in human lung cancer. Clin Cancer Res 13: 1571-1575.
7. Fan D, Yano S, Shinohara H, Solorzano C, Van Arsdall M, et al. (2002) Targeted therapy against human lung cancer in nude mice by high-affinity recombinant antimesothelin single-chain Fv immunotoxin. Mol Cancer Ther 1: 595-600.
8. Yamada S, Tabata C, Tabata R, Fukuoka K, Nakano T, (2011) Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma. Clin Chem Lab Med.
9. Bera TK, Pastan I, (2000) Mesothelin is not required for normal mouse development or reproduction. Mol Cell Biol 20: 2902-2906.
10. Gubbels JA, Belisle J, Onda M, Rancourt C, Migneault M, et al. (2006) Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer 5: 50.
11. Abdel-Azeez HA, Labib HA, Sharaf SM, Refai AN, (2010) HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses. Asian Pac J Cancer Prev 11: 111-116.
12. Yamashita Y, Yokoyama M, Kobayashi E, Takai S, Hino O, (2000) Mapping and determination of the cDNA sequence of the Erc gene preferentially expressed in renal cell carcinoma in the Tsc2 gene mutant (Eker) rat model. Biochem Biophys Res Commun 275: 134-140.
13. Mak BC, Takemaru K, Kenerson HL, Moon RT, Yeung RS, (2003) The tuberin-hamartin complex negatively regulates beta-catenin signaling activity. J Biol Chem 278: 5947-5951.
14. Baba K, Ishigami S, Arigami T, Uenosono Y, Okumura H, et al. (2012) Mesothelin expression correlates with prolonged patient survival in gastric cancer. J Surg Oncol 105: 195-199.
15. Chang MC, Chen CA, Chen PJ, Chiang YC, Chen YL, et al. (2011) Mesothelin Enhances Invasion of Ovarian Cancer by Inducing MMP-7 through MAPK/ERK and JNK Pathways. Biochem J.
16. Bharadwaj U, Marin-Muller C, Li M, Chen C, Yao Q, (2011) Mesothelin overexpression promotes autocrine IL-6/sIL-6R trans-signaling to stimulate pancreatic cancer cell proliferation. Carcinogenesis 32: 1013-1024.
17. Bharadwaj U, Marin-Muller C, Li M, Chen C, Yao Q, (2011) Mesothelin confers pancreatic cancer cell resistance to TNF-alpha-induced apoptosis through Akt/PI3K/NF-kappaB activation and IL-6/Mcl-1 overexpression. Mol Cancer 10: 106.
18. Prieve MG, Moon RT, (2003) Stromelysin-1 and mesothelin are differentially regulated by Wnt-5a and Wnt-1 in C57 mg mouse mammary epithelial cells. BMC Dev Biol 3: 2.
19. Breidenbach M, Rein DT, Everts M, Glasgow JN, Wang M, et al. (2005) Mesothelin-mediated targeting of adenoviral vectors for ovarian cancer gene therapy. Gene Ther 12: 187-193.
20. Hassan R, Bullock S, Premkumar A, Kreitman RJ, Kindler H, et al. (2007) Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res 13: 5144-5149.
21. Hassan R, Lerner MR, Benbrook D, Lightfoot SA, Brackett DJ, et al. (2002) Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitro. Clin Cancer Res 8: 3520-3526.
22. Hassan R, Viner JL, Wang QC, Margulies I, Kreitman RJ, et al. (2000) Anti-tumor activity of K1-LysPE38QQR, an immunotoxin targeting mesothelin, a cell-surface antigen overexpressed in ovarian cancer and malignant mesothelioma. J Immunother (1997) 23: 473-479.
23. Hassan R, Williams-Gould J, Steinberg SM, Liewehr DJ, Yokokawa J, et al. (2006) Tumor-directed radiation and the immunotoxin SS1P in the treatment of mesothelin-expressing tumor xenografts. Clin Cancer Res 12: 4983-4988.
24. Hassan R, Wu C, Brechbiel MW, Margulies I, Kreitman RJ, et al. (1999) 111Indium-labeled monoclonal antibody K1: biodistribution study in nude mice bearing a human carcinoma xenograft expressing mesothelin. Int J Cancer 80: 559-563.
25. Karlan BY, Amin W, Band V, Zurawski VR Jr, Littlefield BA, (1988) Plasminogen activator secretion by established lines of human ovarian carcinoma cells in vitro. Gynecol Oncol 31: 103-112.
26. Bodempudi V, Yamoutpoor F, Pan W, Dudek AZ, Esfandyari T, et al. (2009) Ral overactivation in malignant peripheral nerve sheath tumors. Mol Cell Biol 29: 3964-3974.
27. Yamoutpour F, Bodempudi V, Park SE, Pan W, Mauzy MJ, et al. (2008) Gene silencing for epidermal growth factor receptor variant III induces cell-specific cytotoxicity. Mol Cancer Ther 7: 3586-3597.
28. Hassan R, Cohen SJ, Phillips M, Pastan I, Sharon E, et al. (2010) Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers. Clin Cancer Res 16: 6132-6138.
29. Kreitman RJ, Hassan R, Fitzgerald DJ, Pastan I, (2009) Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. Clin Cancer Res 15: 5274-5279.
30. Chang K, Pastan I, Willingham MC, (1992) Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int J Cancer 50: 373-381.
31. Muminova ZE, Strong TV, Shaw DR, (2004) Characterization of human mesothelin transcripts in ovarian and pancreatic cancer. BMC Cancer 4: 19.
32. Alvarado Y, Giles FJ, (2007) Ras as a therapeutic target in hematologic malignancies. Expert Opin Emerg Drugs 12: 271-284.
33. Scharovsky OG, Rozados VR, Gervasoni SI, Matar P, (2000) Inhibition of ras oncogene: a novel approach to antineoplastic therapy. J Biomed Sci 7: 292-298.
34. Zebisch A, Czernilofsky AP, Keri G, Smigelskaite J, Sill H, et al. (2007) Signaling through RAS-RAF-MEK-ERK: from basics to bedside. Curr Med Chem 14: 601-623.
35. Hilger RA, Scheulen ME, Strumberg D, (2002) The Ras-Raf-MEK-ERK pathway in the treatment of cancer. Onkologie 25: 511-518.
36. Roberts PJ, Der CJ, (2007) Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26: 3291-3310.
37. Chang F, Lee JT, Navolanic PM, Steelman LS, Shelton JG, et al. (2003) Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 17: 590-603.
38. Debacq-Chainiaux F, Boilan E, Dedessus Le Moutier J, Weemaels G, Toussaint O, (2010) p38(MAPK) in the senescence of human and murine fibroblasts. Adv Exp Med Biol 694: 126-137.
39. Singh A, Settleman J, (2010) EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29: 4741-4751.
40. Micalizzi DS, Farabaugh SM, Ford HL, (2010) Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression. J Mammary Gland Biol Neoplasia 15: 117-134.
41. Yilmaz M, Christofori G, (2009) EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev 28: 15-33.
42. Alves CC, Carneiro F, Hoefler H, Becker KF, (2009) Role of the epithelial-mesenchymal transition regulator Slug in primary human cancers. Front Biosci 14: 3035-3050.
43. Bolos V, Peinado H, Perez-Moreno MA, Fraga MF, Esteller M, et al. (2003) The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors. J Cell Sci 116: 499-511.
44. Banhegyi G, Baumeister P, Benedetti A, Dong D, Fu Y, et al. (2007) Endoplasmic reticulum stress. Ann N Y Acad Sci 1113: 58-71.
45. Boelens J, Lust S, Offner F, Bracke ME, Vanhoecke BW, (2007) Review. The endoplasmic reticulum: a target for new anticancer drugs. In Vivo 21: 215-226.
46. Koumenis C, (2006) ER stress, hypoxia tolerance and tumor progression. Curr Mol Med 6: 55-69.
47. Lee AS, Hendershot LM, (2006) ER stress and cancer. Cancer Biol Ther 5: 721-722.
48. Araki K, Nagata K, (2011) Functional in vitro analysis of ERO1 and protein-disulfide isomerase (PDI) pathway. J Biol Chem.
49. Ni M, Lee AS, (2007) ER chaperones in mammalian development and human diseases. FEBS Lett 581: 3641-3651.
50. Kohno K, Normington K, Sambrook J, Gething MJ, Mori K, (1993) The promoter region of the yeast KAR2 (BiP) gene contains a regulatory domain that responds to the presence of unfolded proteins in the endoplasmic reticulum. Mol Cell Biol 13: 877-890.
51. Rovira C, Guida MC, Cayota A, (2010) MicroRNAs and other small silencing RNAs in cancer. IUBMB Life 62: 859-868.
52. Couto LB, High KA, (2010) Viral vector-mediated RNA interference. Curr Opin Pharmacol 10: 534-542.
53. Hokaiwado N, Takeshita F, Banas A, Ochiya T, (2008) RNAi-based drug discovery and its application to therapeutics. IDrugs 11: 274-278.
54. Carthew RW, Sontheimer EJ, (2009) Origins and Mechanisms of miRNAs and siRNAs. Cell 136: 642-655.
55. Bartel DP, (2009) MicroRNAs: target recognition and regulatory functions. Cell 136: 215-233.
56. Quintela-Fandino M, Gonzalez-Martin A, Colomer R, (2010) Targeting cytoskeleton reorganisation as antimetastatic treatment. Clin Transl Oncol 12: 662-669.
57. Hall A, (2009) The cytoskeleton and cancer. Cancer Metastasis Rev 28: 5-14.